Document Detail


Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome.
MedLine Citation:
PMID:  20650041     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome. METHODS: 40 patients with IgA nephropathy manifesting with nephrotic syndrome were randomly divided into two groups. The treatment group was administered with a combination therapy of prednisone and LEF, and the control group with a combination therapy of prednisone and MMF. For the following comparison 24-h urinary protein excretion and the serum levels of albumin, cholesterol, and creatinine before and after the therapy were assessed. RESULTS: In the treatment group, the medication was markedly effective in 5 cases and effective in 7 cases; the total efficacy rate was 60.0%. In the control group, the treatment was markedly effective in 5 cases and effective in 8 cases; the total efficacy rate was 65.0%. The IgA levels in both groups decreased after therapy. There were no significant differences between the results for the two groups (p > 0.05). The treatments were well tolerated in both groups. CONCLUSION: LEF is a safe and effective drug for the treatment of IgA nephropathy manifesting with nephrotic syndrome.
Authors:
X W Liu; D M Li; G S Xu; S R Sun
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  48     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-09-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  509-13     Citation Subset:  IM    
Affiliation:
Department of Nephrology, and 2Information Section, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. liuxiaow@fmmu.edu.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anti-Inflammatory Agents / adverse effects,  therapeutic use
Drug Therapy, Combination
Female
Glomerulonephritis, IGA / drug therapy*,  physiopathology
Humans
Immunoglobulin A / blood
Immunosuppressive Agents / adverse effects,  therapeutic use*
Isoxazoles / adverse effects,  therapeutic use*
Male
Middle Aged
Mycophenolic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Nephrotic Syndrome / drug therapy,  etiology
Prednisone / adverse effects,  therapeutic use
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Immunoglobulin A; 0/Immunosuppressive Agents; 0/Isoxazoles; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 53-03-2/Prednisone; 75706-12-6/leflunomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening for G71R mutation of the UDP-glucuronosyltransferase 1 (UGT1A1) gene in neonates with path...
Next Document:  Irreversible sensorineural hearing loss: an unusual side effect of non-steroidal anti-inflammatory d...